Claims
- 1. A method of altering a hypothalamic function of an individual, said method comprising:
- providing a 19-nor-cholane of the formula ##STR75## wherein P.sub.1 is oxo, .alpha.- or .beta.-hydroxy, .alpha.- or .beta.-acetoxy, .alpha.- or .beta.-propionoxy, .alpha.- or .beta.-lower alkoxy, .alpha.- or .beta.-lower acyloxy or .alpha.- or .beta.-benzyloxy;
- "a", "b", "c", "d", "e", "f", "g", "h", "i", "j", "m", "s" and "n" are alternative sites for optional double bonds, and "k" may be absent or present with "j" to form a triple bond;
- P.sub.2 is hydroxy, hydrogen, lower alkoxy of 1 to 6 carbon atoms, or P.sub.2 is absent;
- P.sub.3 is oxo, hydrogen, hydroxy, lower alkoxy of 1-6 carbon atoms or halo;
- P.sub.4 is methyl or ethyl;
- each P.sub.5 and P.sub.7 is independently is hydrogen, methyl or halo;
- P.sub.6 is hydrogen or methyl;
- R' and R" are independently, hydrogen halo, or are absent, or together form .dbd.CH.sub.2 ;
- and q is an integer from 0 to 2;
- on the surface of nasal neuroepithelial cell having a receptor of said individual wherein said cell is a part of tissue other than olfactory epithelia; and
- administering said 19-nor-cholane derivative within a nasal passage of said individual such that said 19-nor-cholane binds specifically to said receptor and results in an alteration of hypothalamic function of said individual.
- 2. A method of altering an autonomic function of an individual, said method comprising:
- providing a 19-nor-cholane of the formula ##STR76## wherein P.sub.1 is oxo, .alpha.- or .beta.-hydroxy, .alpha.- or .beta.-acetoxy, .alpha.- or .beta.-propionoxy, .alpha.- or .beta.-lower alkoxy, .alpha.- or .beta.-lower acyloxy or .alpha.- or .beta.-benzyloxy;
- "a", "b", "c", "d", "e", "f", "g", "h", "i", "j", "m", "s" and "n" are alternative sites for optional double bonds, and "k" may be absent or present with "j" to form a triple bond;
- P.sub.2 is hydroxy, hydrogen, lower alkoxy of 1 to 6 carbon atoms, or P.sub.2 is absent;
- P.sub.3 is oxo, hydrogen, hydroxy, lower alkoxy of 1-6 carbon atoms or halo;
- P.sub.4 is methyl or ethyl;
- each P.sub.5 and P.sub.7 is independently is hydrogen, methyl or halo;
- P.sub.6 is hydrogen or methyl;
- R' and R" are independently, hydrogen halo, or are absent, or together form .dbd.CH.sub.2 ;
- and q is an integer from 0 to 2;
- on the surface of nasal neuroepithelial cell having a receptor of said individual wherein said cell is a part of tissue other than olfactory epithelia; and
- administering said 19-nor-cholane within a nasal passage of said individual such that said 19-nor-cholane binds specifically to said receptor and results in an alteration of hypothalamic function of said individual.
- 3. The method of claim 2, wherein said neuroepithelial cell is located within a vomeronasal organ of said individual.
- 4. A method according to claim 3 wherein "a", "e" and "d" are double bonds.
- 5. A method according to claim 4 wherein "h" is a double bond.
- 6. A method according to claim 4 wherein "g" is a double bond.
- 7. A method according to claim 6 wherein "n" is a double bond.
- 8. A method according to claim 3 wherein "d" is a double bond.
- 9. A method according to claim 8 wherein "b" is a double bond.
- 10. A method according to claim 2 wherein "c" is a double bond.
- 11. A method according to claim 4 wherein "s" is a double bond.
- 12. The method of any of claims 1 through 11 wherein the amount of said 19-nor-cholane derivative that is administered is at least about 100 picograms, but no more than about 100 micrograms.
- 13. The method of claim 1 wherein the amount of said 19-nor-cholane that is administered is at least about 1 nanograms, but no more than about 10 micrograms.
- 14. The method of claim 13 wherein the amount of said 19-nor-cholane that is administered is at least about 10 nanograms, but no more than about 1 microgram.
- 15. The method of any of claims 1 through 11 further comprising preparing a pharmaceutical composition of said 19-nor-cholane dissolved in a pharmaceutically acceptable carrier.
- 16. The method of claim 15 wherein said pharmaceutical composition is an ointment.
- 17. The method of claim 15 wherein said pharmaceutical composition is liquid.
- 18. The method of claim 15 wherein the administration is by aerosol.
- 19. The method of claims 1 through 11 wherein more than one 19-nor-cholane is administered.
CROSS REFERENCE TO RELATED APPLICATIONS
This application is related to U.S. application Ser. No. 08/127,908, filed Sep. 28, 1993 now abandoned, which is a continuation-in-part of U.S. application Ser. No. 07/903,604, filed Jun. 24, 1992, now abandoned, which in turn is a continuation-in-part of U.S. application Ser. No. 07/708,936, filed May 31, 1991, now abandoned, which in turn is a continuation-in-part of U.S. application Ser. No. 07/638,185, filed Jan. 7, 1991, now abandoned.
The application also relates to U.S. application Ser. No. 08/127,980 filed Sep. 28, 1993 now U.S. Pat. No. 5,783,571, which is another continuation-in-part of U.S. patent application Ser. No. 07/903,604, now abandoned, U.S. patent application Ser. No. 08/077,359, filed Jun. 15, 1993, now abandoned and to commonly assigned, co-pending U.S. patent application Ser. No. 07/903,525, filed Jun. 24, 1992 now abandoned, (a continuation-in-part of U.S. application Ser. No. 07/707,862, filed May 31, 1991, now abandoned, which in turn is a continuation in-part of U.S. application Ser. No. 07/638,743, filed Jan. 7, 1991, now abandoned) entitled "Estrene Steroids as Neurochemical Initiators of Change in Human Hypothalamic Function and Related Pharmaceutical Compositions and Methods"; and to the commonly assigned, co-pending continuation-in-part of Ser. No. 07/903,525, now abandoned and U.S. patent application Ser. No. 08/077,140 now abandoned. The aforementioned U.S. patent applications are each incorporated herein by reference.
Finally, this application may relate to U.S. Patent Application entitled "Fragrance Compositions Containing Human Pheromones", filed Mar. 24, 1992, U.S. Ser. No. 07/856,435 now abandoned.
US Referenced Citations (2)
Number |
Name |
Date |
Kind |
5002753 |
Zeicher et al. |
Mar 1991 |
|
5563131 |
Berliner et al. |
Oct 1996 |
|
Foreign Referenced Citations (3)
Number |
Date |
Country |
WO9428903 |
Dec 1994 |
WOX |
WO 9604296 A1 |
Feb 1996 |
WOX |
WO 9640727 A1 |
Dec 1996 |
WOX |